® The national marketing meeting for the indications of gastric cancer and hepatocellular carcinoma was successfully held

Current status and progress in the treatment of advanced gastric cancer

Professor Wang Fenghua of the Cancer Hospital of Sun Yat-sen University introduced the current status and progress
of advanced gastric cancer drug treatment.
Advances in second-line drug therapy have focused on targeted therapies, including antivascular therapy and anti-HER2 therapy
.
In antivascular therapy, based on RAINBOW and its bridging trial RAINBOW-Asia study, remoximab combined with paclitaxel significantly improved median PFS and OS, and PFS benefited more significantly in the Chinese group, which has become a new standard
for the second-line treatment of gastric cancer in China.
With the rise of targeted drugs, immunotherapies and the discovery of more targets, the combination therapy strategy of various drugs will surely bring survival benefits
to more patients in the whole process of gastric cancer management.

Professor Peng Zhi from Peking University Cancer Hospital deeply interpreted the exploration
of ramoximab in the second-line treatment of advanced gastric cancer.
The excellent efficacy of the REGARD, RAINBOW and RAINBOW-Asia studies has established the standard position
of ramoximab combined with paclitaxel in the second-line treatment of advanced gastric cancer.
Moreover, more exploration of the second-line treatment of ramoximumab has also achieved promising results
.

Professor Taroh Satoh of Osaka University Hospital shared the current status and real-world experience
of antiangiogenic drugs for advanced gastric cancer.
The success of ToGA research kicked off the prelude to targeted therapy for gastric cancer, followed by a series of exploratory studies on multiple targets, but with mixed
results.
Ramoximab acts on VEGFR-2, and its phase III studies REGARD and RAINBOW have achieved positive results, adding new treatment options
for the second-line treatment of advanced gastric cancer.
According to the 6th edition of the Japanese Guidelines for the Treatment of Gastric Cancer, MSI testing is performed before second-line therapy, and patients with MSI-H are recommended pembrolizumab or paclitaxel plus ramoximumab; Paclitaxel plus ramoximumab is recommended in patients with non-MSI-H, so the combination regimen of ramoximab is routinely used in Japan
.
A real-world study in Japan showed that ramoximab combined with paclitaxel after first-line chemotherapy failure can significantly improve survival prognosis, and proper judgment of disease progression is important for subsequent multi-line therapy, and CT influence, clinical symptoms, tumor markers and prognostic factors are also important factors
affecting decision-making.

China-Japan dialogue, collision of ideas

Under the chairmanship of Professor Wang Feng of Sun Yat-sen University Cancer Prevention and Control Center, Professor Taroh Satoh, Professor Chen Kai of the Affiliated Hospital of Soochow University, Professor Ji Youxin of Qingdao Central (Cancer) Hospital, Professor Lin Xiaoyan of Union Hospital Affiliated to Fujian Medical University, Professor Wang Feng of the First Affiliated Hospital of Zhengzhou University, Professor Wang Yusheng of Shanxi Provincial Cancer Hospital, Professor Xiong Jianping of the First Affiliated Hospital of Nanchang University, Professor Zeng Shan of Xiangya Hospital of Central South University, and Professor Zhang Jun of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine participated in the "China-Japan Dialogue" session.
The following views are formed:

• Patients who are HER2-positive, HER2-negative, and have not previously used antiangiogenic drugs can benefit to some extent from ramoximumab plus paclitaxel second-line therapy
  .
  

• There is great heterogeneity of gastric cancer in Eastern and Western populations, and the site of occurrence, biological behavior, etiology, and treatment choice will affect the prognosis
  of patients.
  In general, Japanese doctors have improved the treatment plan during the treatment process to make it more in line with the characteristics of Japanese patients, and pay more attention to the long-term survival benefits of patients, ensuring the efficacy and paying attention to the quality of life of
  patients.
  This also suggests that the implementation of refined management in the treatment of gastric cancer, and the efficacy evaluation focuses on the net benefit rather than tumor enlargement and decrease, which is conducive to optimizing the ultimate benefit
  of patients.
  

• Antiangiogenic therapy plays an important role
  in the treatment of advanced gastric cancer.
  How to consider the positioning of antiangiogenic therapy, how to choose drugs, and whether there are opportunities for cross-line therapy, the most important thing is to pay attention to the weight
  of the vascular microenvironment in the dynamic process of advanced gastric cancer.
  Anti-angiogenic therapy lacks specific biomarker, and based on the response status (depth of response, survival benefit) of tumor manifestations in the second line of ramoximab therapy, it indirectly determines whether the tumor is angiogenesis-dependent, thereby determining the third-line treatment strategy
  .
  

The "Hope to Build a Stomach" advanced gastric cancer case project was launched

Under the chairmanship of Professor Tang Yong of Xinjiang Cancer Hospital, all guests witnessed the launching ceremony
of the "Hope to Build a Stomach" advanced gastric cancer case project.